Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingshan Cai

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
BMC Infectious Diseases|December 26, 2025
Pediatric drug-sensitive tuberculosis treatment regimen profiles and treatment outcomes in mainland China, 2017-2022: a multi-center studyXinxin Zeng, Hao Xu, Aole Li, et al.
Journal of Infection and Public Health|November 13, 2025
The safety of pyrazinamide in pediatric drug-sensitive tuberculosis treatment: A real-world studyXinxin Zeng, Hao Yao, Aole Li, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 13, 2026
Rifapentine Dosing for Drug-Susceptible Tuberculosis: Stage 1 of a Seamless Phase 2/3 Randomized Clinical TrialYang Li, Lingyun Song, Zhen Feng, et al.
BMC Medicine|September 19, 2024
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 7, 2019
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility studyOnno Akkerman, Alena Aleksa, Jan-Willem Alffenaar, et al.
The European Respiratory Journal|October 12, 2019
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global reportSergey Borisov, Edvardas Danila, Andrei Maryandyshev, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
BMC Infectious Diseases|December 26, 2025
Pediatric drug-sensitive tuberculosis treatment regimen profiles and treatment outcomes in mainland China, 2017-2022: a multi-center studyXinxin Zeng, Hao Xu, Aole Li, et al.
Journal of Infection and Public Health|November 13, 2025
The safety of pyrazinamide in pediatric drug-sensitive tuberculosis treatment: A real-world studyXinxin Zeng, Hao Yao, Aole Li, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 13, 2026
Rifapentine Dosing for Drug-Susceptible Tuberculosis: Stage 1 of a Seamless Phase 2/3 Randomized Clinical TrialYang Li, Lingyun Song, Zhen Feng, et al.
BMC Medicine|September 19, 2024
Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in ChinaYanhua Song, Wei Shu, Yi Pei, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 7, 2019
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility studyOnno Akkerman, Alena Aleksa, Jan-Willem Alffenaar, et al.
The European Respiratory Journal|October 12, 2019
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global reportSergey Borisov, Edvardas Danila, Andrei Maryandyshev, et al.
Pageof 3